Form 4: Beam Therapeutics SVP, Finance and Treasurer Bethany J. Cavanagh Sells Shares Under 10b5-1 Plan

Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,287 shares of common stock at $35 per share on February 18, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On February 18, 2025, Bethany J. Cavanagh, the SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,287 shares of common stock.
• The sale was executed at a price of $35 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on September 18, 2024.
• Following the transaction, Cavanagh directly owns 37,527 shares of Beam Therapeutics Inc.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency of trading by corporate insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Insider sales are common, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information.
• Comparable companies such as CRISPR Therapeutics and Editas Medicine also see regular Form 4 filings from their executives.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates